Tetraphase Pharmaceuticals' Xerava (eravacycline) Receives FDA's Approval for Complicated Intra-Abdominal Infections (CIAI)
Shots:
- The approval is based on the two P-III IGNITE study assessing Xerava (eravacycline- bid- IV) vs ertapenem & meropenem in patients with cIAI
- The study demonstrated a non-inferiority data clinical response vs ertapenem with well-tolerated results and achieved high cure rates in patients with Gram-negative pathogens- including resistant isolates
- Xerava (eravacyclin- IV) is a novel fully-synthetic fluorocycline- has also received CHMP approval for CIAI in H1’18 and will be available in Q4’18
Ref: TetraPhase | Image: Twitter
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]
